Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 294

1.

Patient-Reported Outcomes in Patients Chronic Viral Hepatitis without Cirrhosis: The Impact of Hepatitis B and C Viral Replication.

Younossi ZM, Stepanova M, Younossi I, Papatheodoridis G, Janssen HLA, Agarwal K, Nguyen MH, Gane E, Tsai N, Nader F.

Liver Int. 2019 Jun 7. doi: 10.1111/liv.14171. [Epub ahead of print]

PMID:
31173468
2.

An Evaluation of Diagnosis-Related Group (DRG) Implementation Focused on Cancer DRGs in Greek Public Hospitals.

Panagiotopoulos P, Maniadakis N, Papatheodoridis G, Pektasidis D.

Pharmacoecon Open. 2019 May 20. doi: 10.1007/s41669-019-0146-z. [Epub ahead of print]

3.

Role of Spleen Stiffness Measurement by 2D-Shear Wave Elastography in Ruling Out the Presence of High-Risk Varices in Cirrhotic Patients.

Karagiannakis DS, Voulgaris T, Koureta E, Chloupi E, Papatheodoridis GV, Vlachogiannakos J.

Dig Dis Sci. 2019 Apr 15. doi: 10.1007/s10620-019-05616-4. [Epub ahead of print]

PMID:
30989464
4.

Genetic variation in FCER1A predicts peginterferon alfa-2a-induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B.

Wei L, Pavlovic V, Bansal AT, Chen X, Foster GR, He H, Kao JH, Lampertico P, Liaw YF, Motoc A, Papatheodoridis GV, Piratvisuth T, Plesniak R, Wat C.

J Viral Hepat. 2019 Apr 10. doi: 10.1111/jvh.13107. [Epub ahead of print]

PMID:
30972912
5.

Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.

Gountas I, Sypsa V, Papatheodoridis G, Souliotis K, Athanasakis K, Razavi H, Hatzakis A.

World J Gastroenterol. 2019 Mar 21;25(11):1327-1340. doi: 10.3748/wjg.v25.i11.1327.

6.

Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial.

Wedemeyer H, Yurdaydin C, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Keskin O, Port K, Radu M, Celen MK, Idilman R, Weber K, Stift J, Wittkop U, Heidrich B, Mederacke I, von der Leyen H, Dienes HP, Cornberg M, Koch A, Manns MP; HIDIT-II study team.

Lancet Infect Dis. 2019 Mar;19(3):275-286. doi: 10.1016/S1473-3099(18)30663-7.

PMID:
30833068
7.

Can we stop nucleoside analogues before HBsAg loss?

Papatheodoridi M, Papatheodoridis G.

J Viral Hepat. 2019 Feb 25. doi: 10.1111/jvh.13091. [Epub ahead of print] Review.

PMID:
30803099
8.

Immunological biomarkers as indicators for outcome after discontinuation of nucleos(t)ide analogue therapy in patients with HBeAg-negative chronic hepatitis B.

Kranidioti H, Manolakopoulos S, Kontos G, Breen MS, Kourikou A, Deutsch M, Quesada-Del-Bosque ME, Martinez-Nunez RT, Naiyer MM, Woelk CH, Sanchez-Elsner T, Hadziyannis E, Papatheodoridis G, Khakoo SI.

J Viral Hepat. 2019 Jun;26(6):697-709. doi: 10.1111/jvh.13068. Epub 2019 Feb 27.

PMID:
30702196
9.

Hellenic Association for the Study of the Liver Clinical Practice Guidelines: Autoimmune hepatitis.

Dalekos GN, Koskinas J, Papatheodoridis GV.

Ann Gastroenterol. 2019 Jan-Feb;32(1):1-23. doi: 10.20524/aog.2018.0330. Epub 2018 Nov 29.

10.

Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease.

Younossi ZM, Stepanova M, Ong J, Yilmaz Y, Duseja A, Eguchi Y, El Kassas M, Castellanos-Fernandez M, George J, Jacobson IM, Bugianesi E, Wong VW, Arrese M, de Ledinghen V, Romero-Gomez M, Mendez-Sanchez N, Ahmed A, Wong R, Papatheodoridis G, Serfaty L, Younossi I, Nader F, Ziayee M, Afendy A; Global NASH Council.

Clin Gastroenterol Hepatol. 2018 Nov 23. pii: S1542-3565(18)31276-X. doi: 10.1016/j.cgh.2018.11.033. [Epub ahead of print]

PMID:
30476585
11.

The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic disease.

Younossi Z, Papatheodoridis G, Cacoub P, Negro F, Wedemeyer H, Henry L, Hatzakis A.

J Viral Hepat. 2018 Nov;25 Suppl 3:6-14. doi: 10.1111/jvh.13005.

PMID:
30398294
12.

A genotype-specific baseline score predicts post-treatment response to peginterferon alfa-2a in hepatitis B e antigen-negative chronic hepatitis B.

Lampertico P, Messinger D, Cornberg M, Brunetto M, Petersen J, Kennedy P, Asselah T, Rothe V, Caputo A, Bakalos G, Pavlovic V, Papatheodoridis GV.

Ann Gastroenterol. 2018 Nov-Dec;31(6):712-721. doi: 10.20524/aog.2018.0300. Epub 2018 Jul 26.

13.

Evaluation of portal hypertension in the cirrhotic patient: hepatic vein pressure gradient and beyond.

Karagiannakis DS, Voulgaris T, Siakavellas SI, Papatheodoridis GV, Vlachogiannakos J.

Scand J Gastroenterol. 2018 Oct - Nov;53(10-11):1153-1164. doi: 10.1080/00365521.2018.1506046. Epub 2018 Oct 21. Review.

PMID:
30345856
14.

Correction to: Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis.

Ahn SH, Marcellin P, Ma X, Caruntu FA, Tak WY, Elkhashab M, Chuang WL, Tabak F, Mehta R, Petersen J, Guyer W, Jump B, Chan A, Subramanian M, Crans G, Fung S, Buti M, Gaeta GB, Hui AJ, Papatheodoridis G, Flisiak R, Chan HLY.

Dig Dis Sci. 2019 Jan;64(1):285-286. doi: 10.1007/s10620-018-5294-y.

PMID:
30324553
15.

Long-Term Effects of Treatment for Chronic HBV Infection on Patient-Reported Outcomes.

Younossi ZM, Stepanova M, Younossi I, Pan CQ, Janssen HLA, Papatheodoridis G, Nader F.

Clin Gastroenterol Hepatol. 2018 Sep 27. pii: S1542-3565(18)31073-5. doi: 10.1016/j.cgh.2018.09.041. [Epub ahead of print]

PMID:
30268565
16.

Clinical impact of microbiome in patients with decompensated cirrhosis.

Oikonomou T, Papatheodoridis GV, Samarkos M, Goulis I, Cholongitas E.

World J Gastroenterol. 2018 Sep 14;24(34):3813-3820. doi: 10.3748/wjg.v24.i34.3813.

17.

Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy Individuals.

Bazerbachi F, Haffar S, Wang Z, Cabezas J, Arias-Loste MT, Crespo J, Darwish-Murad S, Ikram MA, Olynyk JK, Gan E, Petta S, Berzuini A, Prati D, de Lédinghen V, Wong VW, Del Poggio P, Chávez-Tapia NC, Chen YP, Cheng PN, Yuen MF, Das K, Chowdhury A, Caballeria L, Fabrellas N, Ginès P, Kumar M, Sarin SK, Conti F, Andreone P, Sirli R, Cortez-Pinto H, Carvalhana S, Sugihara T, Kim SU, Parikh P, Chayama K, Corpechot C, Kim KM, Papatheodoridis G, Alsebaey A, Kamath PS, Murad MH, Watt KD.

Clin Gastroenterol Hepatol. 2019 Jan;17(1):54-64.e1. doi: 10.1016/j.cgh.2018.08.069. Epub 2018 Sep 7. Review.

PMID:
30196155
18.

Clinical and epidemiological characteristics of hepatitis C virus-infected people who inject drugs: a Greek descriptive analysis.

Kranidioti H, Chatzievagelinou C, Protopapas A, Papatheodoridi M, Zisimopoulos K, Evangelidou E, Antonakaki P, Vlachogiannakos J, Triantos C, Elefsiniotis I, Goulis J, Mela M, Anagnostou O, Tsoulas C, Deutsch M, Papatheodoridis G, Manolakopoulos S.

Ann Gastroenterol. 2018 Sep-Oct;31(5):598-603. doi: 10.20524/aog.2018.0293. Epub 2018 Jul 19.

19.

Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis.

Ahn SH, Marcellin P, Ma X, Caruntu FA, Tak WY, Elkhashab M, Chuang WL, Tabak F, Mehta R, Petersen J, Guyer W, Jump B, Chan A, Subramanian M, Crans G, Fung S, Buti M, Gaeta GB, Hui AJ, Papatheodoridis G, Flisiak R, Chan HLY.

Dig Dis Sci. 2018 Dec;63(12):3487-3497. doi: 10.1007/s10620-018-5251-9. Epub 2018 Aug 22. Erratum in: Dig Dis Sci. 2018 Oct 15;:.

20.

Correction: DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B.

Papatheodoridis GV, Rigopoulou EI, Papatheodoridi M, Zachou K, Xourafas V, Gatselis N, Hadziyannis E, Vlachogiannakos J, Manolakopoulos S, Dalekos GN.

Antivir Ther. 2018;23(8):711. doi: 10.3851/IMP3261. No abstract available.

PMID:
30091421

Supplemental Content

Loading ...
Support Center